Neuren Pharmaceuticals

US And EU Regulation Will Erode Prospects Yet Offer Hope

AnalystLowTarget

Not Invested

Community Contributor

Published

22 Aug 25

AnalystLowTarget's Fair Value

AU$21.20

3.5% overvalued

22 Aug

AU$21.94

77.7%

4.8%

77.7%

4.8%

You can edit this narrative until Aug 22 10:35 PM. Then, changes will post as Updates.

Author's Valuation

AU$21.23.5% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

AU$21.2

3.5% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

3.22%

Pharma revenue growth rate

0.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.48%

Calculation

AU$10.72m

Earnings '28

281.73x

PE Ratio '28

AU$3.02b

Market Cap '28

AU$3.02b

Market Cap '28

117.22m

No. shares '28

AU$25.76

Share Price '28

AU$25.76 Share Price '28

Discounted to 2025 @ 6.48% p.a.

AU$21.34

Fair Value '25